Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Association of sex with clinical outcomes in COVID-19 patients: A retrospective analysis of 1190 cases

Jiao Liu a,1, Lidi Zhang a,1, Yizhu Chen a,1, Zhixiong Wu b,1, Xuan Dong c,1, Jean-Louis Teboul d,1, Sheng Zhang a, Xiaofei Ye e, Yongan Liu a, Tao Wang a, Hangxiang Du a, Wenzhe Li a, Dechang Chen a,b*

a Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
b Department of Surgical Intensive Care Unit, Huadong Hospital Affiliated to Fudan University, Shanghai, China
c Tuberculosis and Respiratory Department, Wuhan Infectious Disease Hospital, Wuhan, China
d Service de Médecine-Intensive Réanimation, Hospital Bicêtre, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, France
e Department of Health Statistics, Second Military Medical University, Shanghai, China

Keywords:
COVID-19
Sex
Organ failure
Mortality

ABSTRACT

Background: The outbreak of COVID-19 caused by SARS-CoV-2 has been a pandemic. The objective of our study was to explore the association between sex and clinical outcomes in patients with COVID-19.

Methods: Detailed clinical data including clinical characteristics, laboratory tests, imaging features and treatments of 1190 cases of adult patients with confirmed COVID-19 were retrospectively analyzed. Associations between sex and clinical outcomes were identified by multivariable Cox regression analysis.

Results: There were 635 (53.4%) male and 555 (46.6%) female patients in this study. Higher rates of acute kidney injury (5.5% vs. 2.9%, p = 0.026), acute cardiac injury (9.1% vs. 4.3%, p = 0.001), and disseminated intravascular coagulation (2.5% vs. 0.7%, P = 0.024) were observed in males. Compared with female patients, male patients with COVID-19 had a higher inhospital mortality rate (15.7% vs. 10.3%, p = 0.005). However, Cox regression analysis showed that sex did not influence inhospital mortality of COVID-19 patients.

Conclusions: Male sex was associated with a worse prognosis of COVID-19, but it seems not to be an independent prognostic factor.

1. Background

The outbreak of novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1], has rapidly turn into a pandemic. To 26 July 2020, it has affected more than 15,700,000 cases and claimed more than 640,000 lives (http://covid19.who.int). Although the disease is now better contained in China, the prevalence in other parts of the world remains serious. Researches on underlying mechanism of COVID-19 outcomes become urgent worldwide.

Published studies from multiple countries on clinical characteristics of the disease have indicated that males appear with higher incidence and mortality of COVID-19 than females [2–5]. One study of 44672 patients with confirmed COVID-19 in Mainland China, carried out by the Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, found the male-to-female ratio in China overall was 1.06:1, case fatality rate for males was 2.8% and for females was 1.7% [3]. In a study of 1099 patients with COVID-19 from 552 hospitals in 30 provinces in China, the male-to-female ratio was 1.39:1 [4]. Italian epidemiologic data showed the male-to-female ratio was up to 3:1 for SARS-CoV-2 infection [5].

Given the sex-based disparity in incidence and hospitalization, as well as in mortality, the clinical characteristics of the disease need to be stratified by sex. In the present study, we analyzed 1190 adult patients with confirmed COVID-19 in Wuhan Infectious Disease Hospital, to explore the association between sex and clinical outcomes of COVID-19 in Chinese population.

* Corresponding author. Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
E-mail address: cdc12064@rjhn.com.cn (D. Chen).
1 These authors contributed equally to this work.

https://doi.org/10.1016/j.rmed.2020.106159
Received 22 May 2020; Received in revised form 13 August 2020; Accepted 15 September 2020
Available online 28 September 2020
0954-6111/© 2020 Elsevier Ltd. This article is made available under the Elsevier license (http://www.elsevier.com/open-access/userlicense/1.0/).
2. Methods

2.1. Patient population

This study was approved by the Medicine Institutional Review Board of Wuhan Infectious Disease Hospital (KY-2020-03.01). Patients between the ages of 18 and 94 years with confirmed COVID-19 admitted to Wuhan Infectious Disease Hospital from December 29, 2019 to February 28, 2020 were enrolled. The clinical outcomes were monitored up to March 2, 2020, the final date of follow-up.

All patients enrolled in this study were diagnosed according to World Health Organization interim guidance [6]. Nasal and pharyngeal-swab specimens from patients with history of epidemiology and characteristics of virus pneumonia in chest computed tomographic (CT) or X-ray were obtained. Patients with positive results from high-throughput sequencing or real-time reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay of nasal and pharyngeal swab specimens were confirmed with COVID-19.

2.2. Data collection

Epidemiological, demographic, clinical, laboratory and radiological data, treatments and outcomes data were extracted from medical records. The data were reviewed by a trained team of physicians. Information collected included age, sex, comorbidities, exposure history, laboratory findings, chest CT and X-ray scans, respiratory support during hospitalization, therapeutic strategy and outcomes.

Acute respiratory distress syndrome (ARDS) was defined according to the Berlin definition [7]. Acute kidney injury (AKI) was identified according to the Kidney Disease: Improving Global Outcomes definition [8]. Acute cardiac injury (ACI) was defined if the serum levels of cardiac biomarkers were above the 99th percentile upper reference limit or new abnormalities were shown in electrocardiography and echocardiography [9]. Acute hepatic injury (AHI) was identified as total bilirubin increase by 51.3 μmol/L and alanine aminotransferase increase to five times the upper reference limit. Platelet counts, prothrombin time test, and the levels of fibrin/fibrinogen degradation products (FDPs) were components in the major sets of diagnostic criteria of disseminated intravascular coagulation (DIC) [10]. The sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) scores were determined on admission.

2.3. Statistical analysis

Continuous variables were described as mean (95% confidence interval), or as median (interquartile range 25–75% [IQR]), and compared using Student’s t-test or Mann-Whitney U test. Categorical variables were described as number (percentage), and compared using chi-square test or Fisher exact test, as appropriate. The association between sex and inhospital mortality in COVID-19 patients were explored by Cox proportional hazard regression model and displayed as hazard ratios (HR) and 95% confidence intervals (CI). The model was adjusted on prior-decided baseline variables of clinical interest and on those with a p value of less than 0.05 in the univariate analysis. The included variables were: age, sex, comorbidity, SOFA score, lymphocyte, platelet, D-dimer, glucocorticoid and antiviral drugs. A two-sided p value less than 0.05 was defined as statistically significant for all the analyses.

All statistical analyses were performed using SPSS (version 24.0, SPSS Inc., Chicago, IL, USA) and SAS (version 9.4, SAS Institute, Cary, NC).

3. Results

3.1. Demographic and clinical characteristics

1190 adult patients with confirmed COVID-19 were recorded in Wuhan Infectious Disease Hospital during the study period. Of these 1190 patients, 635 (53.4%) were male and 555 (46.6%) were female. Clinical characteristics for males versus females are shown in Table 1. The age distribution as well as clinical symptoms and vital signs on admission had no difference between the two groups. The frequencies of smoking (8.8% vs. 0%, p < 0.001) and drinking (8.8% vs. 2.0%, p < 0.001) were much higher in males. Besides hypertension (males 28.6% vs. females 23.3%, p = 0.037), the comorbidities were similar in the two groups. More female health care workers were infected through occupational exposure than males (2.2% vs. 0.7%, p = 0.025).

3.2. Laboratory and radiologic findings and treatments

There were numerous differences in laboratory findings between male and female patients (Table 2), including higher leucocyte and neutrophil counts, lower lymphocyte and platelet counts, lower CD4/CD8 ratio, longer PT and APTT, higher levels of organ function parameters like TBIL, ALT, AST, BUN, SCR and CK-MB, as well as higher levels of infection or inflammation markers like hsCRP, PCT, serum amyloid A, serum ferritin and IL-6 in males. Stratification by age group revealed that males of all ages had higher levels of organ and coagulation function parameters (e.g. TBIL, ALT, AST, SCR, CK-MB and PT) than those in the age-matched females (Fig. 1). We also analyzed sex differences in chest radiological findings and therapies during hospitalization. The radiological findings were similar in males and females. However, male patients were more likely to receive glucocorticoids during hospitalization than female patients (30.7% vs. 20.6%, p < 0.001).
3.3. Clinical outcomes

Calculations of clinical outcomes were stratified by sex and were summarized in Table 3. Among the 1190 patients, there were 100 male deaths accounted for 63.7% of all deaths, and 57 female deaths accounted for 36.3% of all deaths. The inhospital mortality rate of male patients was significantly higher than that of female patients (15.7% vs. 10.3%, p = 0.005). In male patients, we found significantly higher rates of acute kidney injury (5.5% vs. 2.9%, p = 0.026), acute cardiac injury (9.1% vs. 4.3%, p = 0.001) and DIC (2.5% vs. 0.7%, p = 0.024) than in female patients. However, there were no sex differences in incidence of ARDS, acute hepatic injury or shock. The median length of hospitalization for male patients was 11 days, while that for female patients was 10 days (p = 0.005). Considering that age represents an important issue on clinical outcomes, we compared organ failure and inhospital mortality between males and females in different age groups. As shown in Figs. 2 and 3, the rates of organ failure occurrence and mortality of males and females both increased with age. In patients older than 65 years, male patients had significantly higher incidences of organ failure and inhospital mortality over female patients.

3.4. Multivariable cox regression of inhospital mortality

Our multivariable Cox regression model revealed no relation between sex and inhospital mortality (Table 4). SOFA score on admission (HR 1.057, 95% CI 1.028–1.087, p < 0.001), lymphocytopenia (HR 1.249, 95% CI 1.054–1.479, p = 0.010), thrombocytopenia (HR 1.600, 95% CI 1.142–2.247, p = 0.006) and elevated D-dimer (HR 1.156, 95% CI 1.065–1.255, p < 0.001) were correlated with increased mortality risk during hospitalization. In addition, glucocorticoid and antiviral treatment was negatively associated with inhospital mortality (HR 0.618, 95% CI 0.521–0.735, p < 0.001 and HR 0.747, 95% CI 0.648–0.862, p < 0.001, respectively).

### Table 1
Clinical characteristics of patients with COVID-19 by gender category.

| Age, Median (IQR) | All patients (n = 1190) | Males (n = 635) | Females (n = 555) | P value |
|-------------------|-------------------------|----------------|----------------|--------|
| Distribution-n (%)| 57 (47.67) 56 (46.67) 58 (48.67) | 0.176 |
| <65 yr | 240 (20.2) 144 (22.7) 96 (17.3) | 0.106 |
| 65–74 yr | 266 (22.3) 142 (22.3) 124 (22.3) |
| >75 yr | 305 (25.6) 146 (23.0) 159 (28.7) |
| Smoking-n (%) | 45 (3.8) 45 (7.1) 0 (0) | <0.001 |
| Drinking-n (%) | 48 (4.0) 47 (7.4) 1 (0.2) | <0.001 |
| Comorbidity-n (%) | 0.648, 95% CI 0.521–0.735, p < 0.001 and HR 0.747, 95% CI 0.648–0.862, p < 0.001, respectively). |

### Table 2
Laboratory findings of patients with COVID-19 by gender category.

| Laboratory findings, Mean (95%CI) | All patients (n = 1190) | Males (n = 635) | Females (n = 555) | P value |
|-----------------------------------|-------------------------|----------------|----------------|--------|
| Leucocytes (10^9/L) | 8.0 (7.7,8.4) 8.7 (8.2,9.2) 7.3 (6.7,8.0) | <0.001 |
| Neutrophils (10^9/L) | 6.9 (6.4,7.4) 7.8 (7.0,8.7) 5.8 (5.2,6.4) | <0.001 |
| Lymphocytes (10^9/L) | 1.5 (1.3,1.7) 1.4 (1.2,1.6) 1.7 (1.3,2.1) 0.124 |
| Platelets (10^9/ L) | 199 (194,205) 192 (185,200) 207 (200,215) 0.005 |
| CD4 (/uL) | 456 (409,502) 420 (365,474) 260 (237,301) 217 (203,303) 0.742 |
| CD8 (/uL) | 265 (240,291) 210 (190,250) 276 (230,300) 217 (203,303) |
| PT (s) | 13.3 (12.6,14.1) 13.3 (12.6,14.3) 13.1 (11.8,14.4) 0.612 |
| APTT (s) | 29.3 (29.7,31.5) 27.6 (27.2,28.5) 27.6 (27.2,28.5) |
| TT (s) | 19.6 (19.2,20.1) 19.1 (19.0,20.4) 18.9 (18.9,20.1) 0.374 |
| D-dimer (ug/mL) | 7.5 (5.3,9.7) 8.5 (5.5,11.5) 6.4 (3.1,9.7) 0.001 |
| TBI (umol/L) | 16.3 (15.4,17.1) 17.7 (16.6,18.7) 14.6 (13.4,15.9) |
| ALT (U/L) | 62 (55.6,68) 76 (68.8,84) 46 (36.5,55) <0.001 |
| AST (U/L) | 56 (47.6,74) 61 (51.7,70) 50 (35,66) 0.242 |
| BUN (mmol/L) | 7.9 (6.6,10.5) 8.7 (6.9,10.5) 7.9 (6.5,10.5) 0.146 |
| Scr (umol/L) | 89.5 (84.3,94.0) 100.5 (94,310.6) 76.2 (68,837) 0.001 |
| IL-6 (pg/mL) | 24.3 (14.5,34.2) 30.1 (12,18.1) 17.7 (13.5,22.0) 0.001 |
| hsCRP (mg/L) | 57.6 (40.5,73.9) 67.6 (51,79.0) 46.2 (30,55) <0.001 |
| PCT (ng/mL) | 0.7 (0.4,1.0) 0.7 (0.3,1.1) 0.6 (0.1,1.1) 0.008 |
| SAA (mg/L) | 170.6 (157,418.3) 184.4 (174,519.4) 155.1 (135,220) 0.030 |
| Serum ferritin (ng/mL) | 619.2 (553,968.5) 792.2 (682,890.1) 405.3 (358,845.1) <0.001 |
| IL-6 (pg/mL) | 309.1 (275,634.2) 414.7 (360,249.2) 189.4 (156,622.3) <0.001 |

Abbreviation: chronic obstructive pulmonary disease, COPD; sequential organ failure assessment, SOFA; acute physiology and chronic health evaluation II, APACHE II.

4. Discussion

With the intensification of the adverse impact of COVID-19 pandemic to the world, lots of studies on biological and clinical characteristics of the disease have been published. Official Chinese statistics showed that the male-to-female ratio was 1.06:1 in China and the fatality rate for males was 2.8% versus 1.7% for females [3]. Given the sex differences in case fatality rate, the clinical characteristics of the disease need to be stratified by sex.

In our study, male patients showed significantly increased incidence of acute kidney injury, acute cardiac injury and DIC, as well as higher inhospital mortality. Angiotensin-converting enzyme 2 (ACE2), the main binding site for the entry of SARS-CoV-2 into host cells, is predominantly expressed in heart, kidney, and testis [11–13]. This may explain the vulnerability of cardiovascular system and kidney to SARS-CoV-2 infection. However, after stratification by age group, significant gender differences in organ failure and mortality were observed only in patients older than 65 years. Interestingly, males of all ages showed higher levels of organ and coagulation function parameters than that in age-matched female patients. Biological sex, age, as well as
gender-associated lifestyle behaviors and comorbidities might contribute to the disparity between men and women in COVID-19 outcomes.

Unhealthy lifestyle behaviors like smoking and drinking are prevalent in males. Alcohol and pathogenic constituents of tobacco smoke including nitric oxide, carbon monoxide and phenolic free radicals has proved proinflammatory [14–16]. What’s more, active smoking has been shown to raise ACE2 receptor expression in the lungs, which increases SARS-CoV-2 attachment and entry into alveolar epithelial cells [17,18].

Comorbidities that are associated with fatal COVID-19 cases in the study, include diabetes, hypertension, heart disease, stock and chronic obstructive pulmonary disease (Supplementary Table 1). Among these comorbidities, hypertension occurs more frequently in male patients. Obesity, hypertension and diabetes in the context of metabolic syndrome is considered to provide a permissive inflammatory environment that intensifies a rapid development of cytokine storm which is associated with COVID-19 severity [19,20].

Previous studies confirmed that estrogen have a protective effect on vascular endothelial cells [21–23]. Endothelial dysfunction may contribute to acute kidney injury and acute cardiac injury in critically ill patients [24,25]. However, in patients with COVID-19, mechanisms behind the gender differences might not only due to the levels of endogenous hormones, given that laboratory findings in postmenopausal elderly female patients were still superior to their male peers.

Robust immune systems in females might play another positive role in the gender disparity. Firstly, the bi-allelic expressions of several immune regulatory genes which located on the X chromosome (e.g. TLR7, TLR8, FOXP3, CXCR3 and CD40L) contribute to stronger immune response against viruses in women [26–28]. Secondly, a comparison of adaptive immune responses between males and females demonstrates that females generally have higher levels of CD4/CD8 ratio [29]. The sex-based differences in CD4/CD8 ratio also exist in our patients with COVID-19. In addition, several antiviral genes expressed by cytotoxic T cells carry estrogen receptor elements in their promoter and contribute to stronger cytotoxic response in females [30,31]. Thus, females exhibit robust innate and adaptive immune responses to viral infections.

In spite of the marked sex differences in organ function and mortality in the univariate analysis, we found no relation between sex and hospital deaths in multivariable analysis, which showed that SOFA score, lymphocytopenia, thrombocytopenia and elevated D-dimer were all
Sex underlying mechanisms are not strong enough to significantly alter such a complex and multifactorial endpoint inhospital mortality. Clinical outcomes are not only related to patients’ conditions and disease severity, but also closely related to treatment including respiratory support, glucocorticoid and antiviral therapy. In the study, more males were treated with glucocorticoid due to severe disease. COX proportional regression analysis showed that glucocorticoid therapy reduced the inhospital mortality. Although glucocorticoid therapy of COVID-19 remains controversial and might impact the inhospital mortality, but given comparing men vs. women, the main aim of this study, the bias may be minimized.

4.1. Limitations

This study had some limitations. Firstly, although our research was based on a large population, this was a retrospective single-center study with all patients enrolled from Wuhan Infectious Disease Hospital at the early stages of COVID-19 outbreak. The interpretation of our findings might be limited by the sample size. In addition, in the early stages of COVID-19 outbreak, the disease treatment including respiratory support, glucocorticoid and antiviral therapy mainly relied on clinical judgment and experience of the doctors due to lack of evidence-based guidelines, which might impact the inhospital mortality. However, comparing men vs. women, the main aim of this study, the bias may be minimized. Secondly, not all laboratory tests were performed on all patients, which might introduce some biases albeit the use of multiple analytical strategies to increase the robustness of our estimates. Thirdly, we did not have data on menopausal status of female patients, although no significant relationship was identified when we searched the interaction based on the average age of menopause. Finally, there was no long-term follow-up.

5. Conclusion

In summary, male sex was associated with a worse prognosis of COVID-19, but it seems not to be an independent prognostic factor.

CRediT authorship contribution statement

Jiao Liu: drafted the manuscript. Lidi Zhang: drafted the manuscript. Yizhu Chen: collected the clinical data. Zhixiong Wu: collected the clinical data. Xuan Dong: collected the clinical data. Jean-Louis Teboul: drafted the manuscript. Sheng Zhang: did statistical analysis. Xiaofei Ye: did statistical analysis. Yongnan Liu: summarized all the collected data. Tao Wang: summarized all the collected data. Hangxiang Du: summarized all the collected data. Wenzhe Li: summarized all the collected data. Dechang Chen: revised the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

We thank all the staffs in Wuhan Infectious Disease Hospital to take care of COVID-19 patients, and all the patients and their families included in the current study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.rmed.2020.106159.
References

[1] N. Zhu, D.Y. Zhang, W.L. Wang, X.W. Li, B. Yang, J.D. Song, et al., A novel coronavirus from patients with pneumonia in China, N. Engl. J. Med. 382 (8) (2020) 727–733, https://doi.org/10.1056/NEJMoa2001017.

[2] D. Chakravarty, S.S. Nair, N. Hammouda, P. Ratnani, Y. Gharib, V. Wagaskar, et al., Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer, Commun Biol 3 (1) (2020) 374, https://doi.org/10.1038/s42003-020-1088-9.

[3] The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) – China, China CDC Weekly 2 (8) (2020) 113–122, https://doi.org/10.46234/ccdcw2020.032.

[4] W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, et al., Clinical characteristics of 2019 novel coronavirus infection in Wuhan, China, Lancet 395 (10223) (2020) 71–79, https://doi.org/10.1016/S0140-6736(20)30183-5.

[5] ARDS Definition Task Force, V.M. Ranieri, G.D. Rubenfeld, B.T. Thompson, N. Zhang, J.M. Taber, et al., Acute respiratory distress syndrome: the Berlin definition, J. Am. Med. Assoc. 307 (23) (2012) 2526–2533, https://doi.org/10.1001/jama.2012.5669.

[6] World Health Organization, Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection Is Suspected: Interim Guidance, 28 January 2020, https://apps.who.int/iris/handle/10665/330893.

[7] ARDS Definition Task Force, V.M. Ranieri, G.D. Rubenfeld, B.T. Thompson, N. D. Ferguson, E. Caldwell, E. Fan, et al., Acute respiratory distress syndrome: the Berlin definition, J. Am. Med. Assoc. 307 (23) (2012) 2526–2533, https://doi.org/10.1001/jama.2012.5669.

[8] M.D. Okusa, A. Davenport. Reading between the (guide)lines–the KDIGO practice guideline on acute kidney injury in the individual patient. Kidney Int.. 85(1):39-48, https://doi.org/10.1001/jama.2012.5669.

[9] ARDS Definition Task Force, V.M. Ranieri, G.D. Rubenfeld, B.T. Thompson, N. D. Ferguson, E. Caldwell, E. Fan, et al., Acute respiratory distress syndrome: the Berlin definition, J. Am. Med. Assoc. 307 (23) (2012) 2526–2533, https://doi.org/10.1001/jama.2012.5669.

[10] D. Ferguson, E. Caldwell, E. Fan, et al., Acute respiratory distress syndrome: the Berlin definition, J. Am. Med. Assoc. 307 (23) (2012) 2526–2533, https://doi.org/10.1001/jama.2012.5669.

[11] L. Chen, X.J. Li, M.Q. Chen, Y. Feng, C.L. Xiong, The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.

[12] M. Chen, X.J. Li, M.Q. Chen, Y. Feng, C.L. Xiong, The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.

[13] Z. Varga, A.J. Flammer, R. Andermatt, A.S. Zinkernagel, et al., Endothelial cell infection and endotheliitis in COVID-19, Lancet 395 (10234) (2020) 1417–1418, https://doi.org/10.1016/S0140-6736(20)30937-5.

[14] E.Y. Gohar, D.M. Pollock, Sex-specific contributions of endothelin to hypertension, Curr. Hypertens. Rep. 20 (7) (2018) 58, https://doi.org/10.1007/s11906-018-0856-9.

[15] B.Y. Hu, S.Y. Huang, L.H. Yin, The cytokine storm and COVID-19, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.26232.

[16] C.I. Vardavas, K. Nikitar, COVID-19 and smoking: a systematic review of the evidence, Tob. Induc. Dis. 18 (2020) 20, https://doi.org/10.18332/tid/119324.

[17] A.R. Saltiel, J.M. Olefsky, The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases, Front. Immunol. 11 (2020), https://doi.org/10.3389/fimmu.2020.00459.

[18] D. Khan, S.A. Ahmed, The immune system is a natural target for estrogen action: opposing effects of estrogen in two prototypical autoimmune diseases, Front. Immunol. 11 (2020), https://doi.org/10.3389/fimmu.2020.00459.

[19] A. Younes, G. Ronconi, R. Ross, P. Conti, Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy, Front. Immunol. 11 (2020), https://doi.org/10.3389/fimmu.2020.00579.

[20] E.V. Ohali, I. Ohali, Estrogen and the cardiovascular system, Pharmacol. Ther. 124 (2009) 108–122. https://doi:10.1016/j.pharmthera.2012.03.007.

[21] B.Y. Hu, S.Y. Huang, L.H. Yin, The cytokine storm and COVID-19, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.26232.

[22] M.M. Montt-Guevara, G. Pallsa, S. Spina, G. Bernardchi, E. Cecchi, A.E. Campelo, et al., Gender differences in SARS-CoV-2 infection rates and the potential link to prostate cancer, Commun Biol 3 (1) (2020) 374, https://doi.org/10.1038/s42003-020-00070-3.

[23] A.A. Knowlton, A.R. Lee, Estrogen and the cardiovascular system, Pharmacol. Ther. 124 (2009) 108–122. https://doi:10.1016/j.pharmthera.2012.03.007.

[24] K.L. Flanagan, A.L. Fink, M. Plebanski, S.L. Klein, Sex and gender differences in the innate and adaptive immune responses to viruses, and efficacy of prophylaxis molecules that target iron, Biochem. J. 369 (Pt 3) (2003) 429–440, https://doi.org/10.1042/BJ20021302.

[25] F. Walsh, B. Patel, S. Yarlagadda, F.M. Strickland, B.C. Richardson, Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis, Gene Immun. 10 (5) (2009) 509–516, https://doi.org/10.1038/gene.2009.12.